Why the study?
Radiolabeled fibroblast activation protein inhibitors are emerging as promising imaging agents, motivating evaluation of [68Ga]Ga-DATA5m.SA.FAPi for imaging pulmonary fibrosis.
The FAPI tracer [68Ga]Ga-DATA5m.SA.FAPi shows potential as a molecular imaging agent for detecting pulmonary fibrosis, particularly in later stages of the bleomycin-induced mouse model.
This is the authors' abstract. We don't add key points for this paper.
Background/Objectives: Radiolabeled fibroblast activation protein inhibitors (FAPIs) are emerging as promising imaging agents assessing fibrotic diseases. This study evaluates [68Ga]Ga-DATA5m.SA.FAPi for imaging pulmonary fibrosis in two mouse models, bleomycin-induced (BLM) and a transgenic (fra-2tg) model, both displaying characteristics of human pulmonary fibrotic diseases. Methods: In the BLM model, C57BL/6 mice were treated with bleomycin or isotonic sodium chloride (controls) for 4, 5, and 6 weeks, followed by [68Ga]Ga-DATA5m.SA.FAPi PET/CT scans. Fra-2tg mice and wildtype (WT) littermates underwent at 7, 11, and 18/19 weeks of age a PET/CT scan. The selected timepoints correspond to early, middle, and late disease stages for each model. Imaging was complemented by ex vivo quantification, histological, and immunohistochemical (IHC) analyses. Results: In BLM mice, pulmonary [68Ga]Ga-DATA5m.SA.FAPi uptake showed a trend toward increase as early as 5 weeks of treatment compared with the controls, which was confirmed by ex vivo analysis (BLM: 3.31 ± 0.29%ID/g, n = 5; control: 1.61 ± 0.29%ID/g, n = 4; p = 0.0035). In fra-2tg mice, no significant differences could be detected. IHC revealed elevated pulmonary FAP expression specifically at early (BLM) and mild (fra-2tg) disease stages, whereas for BLM, tracer uptake was more pronounced at later stages. Conclusions: Our findings complement and extend observations from previous studies and support the potential of FAPI tracers as molecular imaging agents for pulmonary fibrosis.
Answers are grounded in this paper and cite their sources.
May inform preclinical fibrosis imaging research; leaves open clinical translation of FAPI PET.
No takes yet. Share an insight, caveat, or question.
Weissenböck et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: